Novonesis 9M 2026 interim report with 7% organic growth
FROM THE WIRE · FINANCE.YAHOO.COM
Novonesis (Novozymes A/S) Strong Q3 sales leading to 9M at 7% organic sales growth and adj. EBITDA margin of 37.9%. 2026 outlook confirmed: 7-8% organic sales growth and adj. EBITDA margin at the higher end of the 37-38% range. Ester Baiget, President & CEO: "With strong sales…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarterly report in line with confirmed guidance, with no major surprises for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Organic sales grew 7% in 9M.
- 02Food & Health Biosolutions grew 9% organically.
- 03The 2026 outlook remains confirmed.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets